425: Rallybio Merges with Candid, Secures $505M Financing

Sentiment:

Merger Announcement 2 March 2026 9:37 AM

Rallybio Corporation will acquire clinical-stage Candid Therapeutics in a merger, backed by over $505 million in new financing, to advance a T-cell engager pipeline for autoimmune diseases.

Capital raiseCandid Therapeutics entered into subscription agreements for a concurrent oversubscribed and upsized private financing of over $505.5 million in gross proceeds.The financing syndicate includes leading healthcare institutional investors and mutual funds such as Venrock Healthcare Capital Partners, RA Capital Management, Janus Henderson Investors, accounts advised by T. Rowe Price Associates, Inc., venBio Partners, Viking Global Investors, Cormorant Asset Management, Foresite Capital, Soleus Capital, TCGX, Vivo Capital, and other institutional investors.The financing is expected to close immediately prior to the Merger.The proceeds are expected to provide the combined company with a strong financial foundation, funding operations through 2030.

Better than expectedThe concurrent private financing was "significantly oversubscribed and upsized," indicating strong investor demand beyond initial expectations.The expected pro-forma cash of approximately $700 million at closing is projected to fund operations through 2030, providing a longer runway than typically seen for clinical-stage biotech companies.Rallybio regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing concern.

Summary

Rallybio Corporation is acquiring Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on T-cell engager (TCE) therapeutics for autoimmune diseases, through a reverse-triangular merger.
The combined entity will operate as Candid Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol CDRX.
A concurrent, oversubscribed private financing of over $505.5 million in gross proceeds has been committed to Candid by a syndicate of leading healthcare institutional investors and mutual funds.
Pre-Merger Candid equityholders (including financing investors) are expected to own approximately 96.35% of the combined company, while pre-Merger Rallybio equityholders will own approximately 3.65%.
This ownership split is based on a Rallybio valuation of $47.5 million (assuming $37.5 million net cash at closing) and a Candid valuation of $750.0 million.
The combined company's cash balance at closing is projected to fund operations through 2030, supporting multiple clinical milestones.
Rallybio stockholders prior to the closing will receive Contingent Value Rights (CVRs) entitling them to a portion of cash proceeds from the sale of interests in REV102 and potential disposition of Rallybio's other legacy assets.
The transaction has been unanimously approved by both companies' boards and is expected to close in mid-2026, subject to stockholder and regulatory approvals.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development for Candid Therapeutics, securing substantial funding and a public listing to advance a promising pipeline. While Rallybio shareholders face significant dilution, the CVRs offer a potential upside from legacy assets, and the merger provides a path forward for the company.

Positives

Secured over $505.5 million in gross proceeds from a syndicate of leading healthcare institutional investors and mutual funds, significantly oversubscribed and upsized.
The combined company is expected to be well-capitalized, with cash projected to fund operations through 2030.
Candid Therapeutics brings a diversified pipeline of T-cell engager (TCE) therapeutics for autoimmune diseases, with ongoing clinical studies in over 10 indications.
Cizutamig (BCMA TCE) shows potential as a firstand best-in-class treatment for autoimmune diseases, with favorable tolerability and emerging clinical data suggesting deeper therapeutic activity.
Global Phase 2 studies for cizutamig in myasthenia gravis and interstitial lung disease are planned to initiate in 2026.
CND261 (CD20 TCE) has been dosed in over 100 patients with low rates of CRS and early evidence of deep tissue B-cell depletion.
CND319 (dual targeting CD19 and CD20 TCE) shows promising therapeutic index in non-human primate studies, with first-in-human studies planned for mid-2026.
The combined company will be led by an experienced management team, including Dr. Ken Song as President and CEO, with deep expertise in autoimmune drug development and TCE biology.
Rallybio regained compliance with Nasdaq's $1.00 minimum bid price requirement on February 24, 2026, following a 1-for-8 reverse stock split.

Negatives

Current Rallybio executive officers and directors are expected to resign upon closing.
The CVRs for pre-closing Rallybio stockholders offer no assurance of payment, as there can be no guarantee that any proceeds will be received from the disposition of legacy assets.
Rallybio's valuation for the merger is set at $47.5 million, significantly lower than Candid's $750.0 million, indicating a substantial dilution for existing Rallybio shareholders.
Rallybio's pre-Merger equityholders are expected to own only approximately 3.65% of the combined company.

Risks

Conditions to closing the proposed Merger may not be satisfied, including the failure to timely obtain stockholder approval.
Uncertainties exist regarding the timing of the consummation of the proposed Merger.
Risks related to Rallybio's ability to manage operating expenses and merger-associated expenses pending closing.
Failure or delay in obtaining required approvals from governmental or regulatory entities.
Adjustments to the Exchange Ratio could result in Rallybio's stockholders owning more or less of the combined company than currently anticipated.
Risks related to the market price of Rallybio Common Stock relative to the value suggested by the Exchange Ratio.
Unexpected costs, charges, or expenses may result from the proposed transaction.
The concurrent financing may not be consummated.
Potential for the occurrence of any event, change, or circumstance that could lead to the termination of the merger agreement.
Uncertainties associated with Candid's product candidates and platform technologies, and risks with clinical development and regulatory approval, including potential delays.
Inability of the combined company to obtain sufficient additional capital to advance product candidates and preclinical programs.
Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
Risks related to the failure to realize any value from product candidates and preclinical programs due to inherent difficulties in bringing them to market.
Risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger.
The possibility that holders of CVRs may never receive any proceeds from legacy asset dispositions.

Future Outlook

The combined company, Candid Therapeutics, Inc., expects to operate with a strong financial foundation, with cash projected to fund operations through 2030. This capital is intended to support the advancement of Candid's diversified pipeline of T-cell engager (TCE) programs through multiple clinical milestones, including the initiation and clinical readouts of Phase 2 studies for cizutamig in myasthenia gravis and interstitial lung disease (ILD) secondary to rheumatological diseases in 2026. First-in-human studies for CND319 are planned for mid-2026, and for CND460 in the first half of 2027. The company aims to be a leader in TCEs for autoimmune diseases, pursuing both immune reset and immune dimming dosing approaches.

Management Comments

"This transaction marks an exciting moment for Candid as we lead the development of TCEs for patients with autoimmune diseases. By combining with Rallybio and securing over $505 million in new financing from a distinguished group of healthcare investors, we have the resources to advance what we view as a transformative therapeutic modality." Dr. Ken Song, Chairman, President and Chief Executive Officer of Candid Therapeutics.
"With Phase 2 studies planned for cizutamig in 2026 and a rich pipeline of next-generation TCE programs, we will continue to push forward this new drug class." Dr. Ken Song.
"We are pleased to announce this transaction, which we believe represents a compelling opportunity for Rallybio stockholders to participate in the future value creation of a well-capitalized, clinical-stage company with a differentiated and broad portfolio of TCE drug candidates." Dr. Stephen Uden, Co-Founder and Chief Executive Officer of Rallybio.
"Candids clinical data in myasthenia gravis and across its autoimmune pipeline, combined with the strong endorsement of leading healthcare investors further substantiates the merit of this transaction." Dr. Stephen Uden.

Industry Context

StockSavvy.ai notes that this merger and significant financing round highlight a growing trend in the biotechnology sector: the strategic consolidation of smaller, innovative companies with publicly traded entities to gain access to capital markets and accelerate drug development. The focus on T-cell engager (TCE) therapeutics for autoimmune diseases positions the combined entity in a highly competitive yet potentially lucrative area, mirroring the success seen with CAR-T therapies in oncology and the emerging interest in immune modulation for chronic conditions. The substantial oversubscribed financing from prominent healthcare investors signals strong market confidence in Candid's pipeline and the TCE modality's potential to offer differentiated therapeutic benefits, such as deep B-cell depletion with manageable cytokine release, compared to existing treatments like anti-FcRn drugs or traditional mAbs. This move could set a precedent for similar transactions where private biotech firms leverage public shells for rapid market entry and funding.

Comparison to Industry Standards

Cizutamig's emerging clinical data suggests "deeper therapeutic activity with less frequent dosing than the anti-FcRn drug class." This implies a potential advantage over established therapies like argenx's Vyvgart (efgartigimod) or Alexion's Ultomiris (ravulizumab) in myasthenia gravis, which are anti-FcRn antibodies.
Cizutamig's clinical data in multiple myeloma showed "improved CRS profile with comparable efficacy compared to other BCMA TCEs." This suggests a potentially better safety profile than other BCMA-targeting agents, such as teclistamab (Tecvayli) from Johnson & Johnson, which is approved for multiple myeloma.
CND261 (CD20 TCE) demonstrated "low rates of CRS" in over 100 patients, which could compare favorably to other CD20-targeting agents like rituximab (Rituxan) or obinutuzumab (Gazyva) in terms of cytokine release profile, especially in autoimmune settings.
The "immune reset" and "immune dimming" dosing approaches with TCEs are presented as unique, offering flexibility beyond current standard-of-care treatments which often involve polypharmacy and long-term steroids, or therapies like IVIG with different risk profiles.
The company's strategy to leverage a fully operational team in China for early clinical development is a notable approach to achieve "meaningful cost and time efficiency," a strategy increasingly adopted by global biotech firms to accelerate clinical proof-of-concept.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and Chief Executive Officer	Dr. Stephen Uden	Dr. Ken Song	Effective Time of Merger	Merger of Rallybio with Candid Therapeutics, with Candid's CEO leading the combined entity.
Executive Officers and Directors	Current Rallybio executive officers and directors	NA	In connection with the Closing	Expected to tender their resignations as part of the merger.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Certificate of Incorporation Amendment	The certificate of incorporation of the Surviving Corporation will be amended to read identically to Merger Sub's, and its name will change to Candid Operating Company, Inc.	Effective Time of Merger	Standard procedure for a reverse-triangular merger, establishing the new operating entity's legal identity.
Certificate of Incorporation Amendment	Rallybio's certificate of incorporation will be amended to change its name to Candid Therapeutics, Inc., effect a reverse stock split, and increase the number of authorized shares.	Effective Time of Merger	Reflects the new corporate identity and capital structure of the combined public company, facilitating Nasdaq listing compliance and future equity issuance.
Bylaws Amendment	The bylaws of the Surviving Corporation will be amended to read identically to Merger Sub's.	Effective Time of Merger	Aligns the governance framework of the surviving operating entity with the new corporate structure.
Board Composition Change	The Parent Board will comprise seven members, all designated by Candid.	Immediately after the Effective Time	Ensures Candid's strategic vision and leadership are fully integrated into the combined public company's governance.
Equity Incentive Plans	The Parent Board will approve, adopt, and submit for stockholder approval the 2026 Equity Incentive Plan (up to 15% of post-closing fully diluted shares, with potential 5% annual evergreen increase) and the 2026 Employee Stock Purchase Plan (up to 1% of post-closing fully diluted shares, with potential 1% annual evergreen increase).	Prior to or as of the Effective Time (subject to stockholder approval)	Provides mechanisms for attracting and retaining talent in the combined company through equity compensation, aligning employee incentives with company performance.
Equity Award Vesting	All Parent Stock Awards will be fully vested as of the Effective Time.	Effective Time of Merger	Addresses existing equity compensation for Rallybio employees and directors in anticipation of the merger and management changes.
Indemnification and Insurance	Indemnification provisions for directors and officers of Rallybio and Candid will be maintained for six years post-merger, and a six-year prepaid tail policy for D&O liability insurance will be purchased.	Effective Time of Merger	Protects current and former directors and officers from potential liabilities arising from their service, ensuring continuity of governance protections.

Legal Proceedings

No Legal Proceeding (or basis therefor) pending or threatened against Rallybio or its Subsidiaries, or any present or former officer, director or employee of Rallybio in such individuals capacity as such, that would prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions.
No Legal Proceeding (or basis therefor) pending or threatened against Candid, its properties or assets, or any present or former officer, director or employee of Candid in such individuals capacity as such, that would prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions.

Related Party Transactions

No transactions, agreements, arrangements or understandings between Candid and its affiliates (other than its subsidiaries) since July 1, 2024, that would require disclosure under Item 404 of Regulation S-K.
No transactions, agreements, arrangements or understandings between Rallybio and its affiliates (other than its subsidiaries) since January 1, 2023, that would require disclosure under Item 404 of Regulation S-K and have not been disclosed in Parent SEC Documents.

Stakeholder Impact

Shareholders (Rallybio): Significant dilution (expected to own ~3.65% of combined company), but receive CVRs for legacy assets. Opportunity to participate in a well-capitalized, clinical-stage company with a differentiated pipeline.
Shareholders (Candid): Gain public listing and substantial capital infusion, expected to own ~96.35% of the combined company.
Employees (Rallybio): Current executive officers and directors are expected to resign. Employment agreements for key executives (Stephen Uden, Jonathan Lieber, Steven Ryder) are amended to clarify change in control benefits. Rallybio's preclinical, CMC, and clinical activities will be wound down, implying potential impact on related employees.
Management (Candid): Candid's leadership team, led by Dr. Ken Song, will take over the combined company, indicating continuity and growth opportunities for Candid's personnel.
Patients: Potential for new, transformative T-cell engager therapeutics for autoimmune diseases, with multiple programs advancing to clinical milestones.

Next Steps

Rallybio will prepare and file a registration statement on Form S-4, including a proxy statement and prospectus, with the SEC.
Rallybio will seek approval from its stockholders for the issuance of shares, change of control, a reverse stock split, and the change of the company name to Candid Therapeutics, Inc.
Rallybio will seek stockholder approval for an increase in authorized shares and the Candid 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan.
Candid will seek approval from its stockholders for the adoption of the Merger Agreement and related transactions.
The parties will make filings required under the HSR Act.
The closing of the Merger is expected in mid-2026, subject to satisfaction of closing conditions.
Global Phase 2 studies for cizutamig in myasthenia gravis and interstitial lung disease are planned to initiate in 2026.
First-in-human studies for CND319 are planned for mid-2026.
First-in-human studies for CND460 are planned for 1H 2027.
Rallybio will use commercially reasonable efforts to effect the disposition of its Legacy Assets for one year after the Closing Date.
Rallybio will wind down all preclinical, CMC, and clinical activities during the Pre-Closing Period.

Key Dates

Date	Description
2023-02-01	Effective date of Jonathan Lieber's employment agreement with Rallybio Corporation.
2023-08-01	Effective date of Stephen Uden's second amended and restated employment agreement with Rallybio Corporation.
2023-01-01	Start date for compliance with laws and SEC filings for Rallybio.
2024-07-01	Start date for compliance with laws for Candid Therapeutics.
2024-08-19	Date of Candid's Investors Rights Agreement, Right of First Refusal and Co-Sale Agreement, and Voting Agreement.
2024-09-30	Date of Candid's unaudited financial statements (Company Balance Sheet).
2024-11-15	Date Rallybio issued Pre-Funded Warrants.
2024-12-31	Date of Candid's audited financial statements.
2025-04-07	Date Rallybio's proxy statement was filed with the SEC.
2025-07-08	Date of Membership Interest Purchase Agreement between Rallybio and Recursion Pharmaceuticals, Inc.
2025-09-30	Date of Rallybio's Quarterly Report on Form 10-Q.
2025-06-25	Effective date of Steven Ryder's employment agreement with Rallybio Corporation.
2026-01-26	Rallybio stockholders approved the Reverse Stock Split at a Special Meeting.
2026-02-02	Date of Mutual Confidential Disclosure Agreement between Candid and Rallybio.
2026-02-06	Effective time of Rallybio's 1-for-8 Reverse Stock Split (12:01 a.m. Eastern Time).
2026-02-06	Start date of 11 consecutive business days Rallybio Common Stock had a closing bid price of at least $1.00 per share.
2026-02-23	End date of 11 consecutive business days Rallybio Common Stock had a closing bid price of at least $1.00 per share.
2026-02-24	Rallybio received a letter from Nasdaq notifying it had regained compliance with the $1.00 minimum bid price requirement.
2026-02-26	Reference Date for Parent Capital Stock calculation.
2026-03-01	Date of Agreement and Plan of Merger and Reorganization between Rallybio and Candid Therapeutics.
2026-03-01	Date of Subscription Agreement for Concurrent Financing.
2026-03-01	Effective date of employment agreement amendments for Stephen Uden, Jonathan Lieber, and Steven Ryder.
2026-03-02	Date of joint press release announcing the merger agreement.
2026-03-02	Date of investor presentation and conference call.
2026-05-14	Latest date for Candid to furnish unaudited interim financial statements for inclusion in Registration Statement.
2026-06-01	Expected initiation of first-in-human studies for CND319 (mid-2026).
2026-06-01	Expected initiation of global Phase 2 studies for cizutamig in myasthenia gravis and interstitial lung disease (mid-2026).
2026-06-01	Expected closing of the merger (mid-2026).
2026-09-01	End Date for consummation of Contemplated Transactions (subject to extension).
2027-01-01	Expected first-in-human studies for CND460 (1H 2027).
2030-12-31	End of CVR Term.

Recommendation

strong buy

The merger with Candid Therapeutics, coupled with an oversubscribed $505.5 million financing, provides Rallybio (soon to be Candid Therapeutics, Inc.) with a robust financial runway through 2030 and a highly promising, diversified pipeline of T-cell engager (TCE) therapeutics for autoimmune diseases. The significant investor confidence, evidenced by the upsized financing from leading healthcare funds, validates Candid's platform and clinical strategy. While existing Rallybio shareholders face substantial dilution, the CVRs offer a potential return from legacy assets, and the combined entity's strong capitalization and advanced clinical programs (like cizutamig entering Phase 2 for myasthenia gravis and ILD) present a compelling long-term growth opportunity in a high-unmet-need market. This strategic move transforms Rallybio into a well-funded, focused biotech with a clear path to multiple value-driving clinical milestones, making it a strong buy for investors seeking exposure to innovative autoimmune therapies.

Keywords

Rallybio, Candid Therapeutics, Merger, Biotechnology, T-cell engager, Autoimmune diseases, Cizutamig, BCMA TCE, Myasthenia Gravis, Interstitial Lung Disease, CND261, CD20 TCE, CND319, CD19/CD20 TCE, Drug development, Clinical trials, Private financing, Nasdaq, RLYB, CDRX, Contingent Value Rights, Reverse stock split

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.